Wako to market biopathway system

Biopharmaceutical company GNI Ltd.

Randall C Willis
TOKYO—Biopharmaceutical company GNI Ltd. announced an alliance with Osaka-based Wako Pure Chemical Industries that will see the latter company market Cell Illustrator 3.0, a biopathway modeling tool developed by GNI in cooperation with the University of Tokyo.
 
With the growing interest in systems biology and biological modeling, GNI designed the software to work on a variety of platforms and accept a variety of data types. The system uses a proprietary high-performance visual modeling architecture based on Petri net1.
 
"In biological research today, high speed data analysis is extremely important," explained Dr. Christopher Savoie, GNI chairman, CEO, and founder. "The sales alliance with Wako Pure Chemical is significant because it will introduce more companies and educational institutions to the benefits of Cell Illustrator 3.0 in analyzing genetic networks. In addition, GNI looks forward to helping to cultivate tomorrow's medical professionals by offering a free version of the software that enables students and the general public to simulate biological pathways."  
 
As of April 2007, Wako will sell the software throughout Japan via its 70+ partner agencies.

Randall C Willis

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Front Cover

Latest Issue  

• Volume 18 • Issue 12 • December 2022/January 2023

December 2022/January 2023

December 2022/January 2023 issue